BACKGROUND: The mixed lineage leukemia (MLL) gene is commonly rearranged in infant leukemia (IL). Genetic determinants of susceptibility to IL are unknown. Recent genome-wide association studies for childhood acute lymphoblastic leukemia (ALL) have identified susceptibility loci at IKZF1, ARID5B, and CEBPE. PROCEDURE: We genotyped these loci in 171 infants with leukemia and 384 controls and evaluated associations overall, by subtype [ALL, acute myeloid leukemia (AML)], and by presence (+) or absence (-) of MLL rearrangements. RESULTS: Homozygosity for a variant IKZF1 allele (rs11978267) increased risk of infant AML [Odds ratio (OR) = 3.9, 95% confidence interval (CI) = 1.8-8.4]; the increased risk was similar for AML/MLL+ and MLL- cases. In contrast, risk of ALL/MLL- was increased in infants homozygous for the IKZF1 variant (OR = 5.1, 95% CI = 1.8-14.5) but the variant did not modify risk of ALL/MLL+. For ARID5B (rs10821936), homozygosity for the variant allele increased risk for the ALL/MLL- subgroup only (OR = 7.2, 95% CI = 2.5-20.6). There was little evidence of an association with the CEBP variant (rs2239633). CONCLUSION: IKZF1 is expressed in early hematopoiesis, including precursor myeloid cells. Our data provide the first evidence that IKZF1 modifies susceptibility to infant AML, irrespective of MLL rearrangements, and could provide important new etiologic insights into this rare and heterogeneous hematopoietic malignancy.
BACKGROUND: The mixed lineage leukemia (MLL) gene is commonly rearranged in infantleukemia (IL). Genetic determinants of susceptibility to IL are unknown. Recent genome-wide association studies for childhood acute lymphoblastic leukemia (ALL) have identified susceptibility loci at IKZF1, ARID5B, and CEBPE. PROCEDURE: We genotyped these loci in 171 infants with leukemia and 384 controls and evaluated associations overall, by subtype [ALL, acute myeloid leukemia (AML)], and by presence (+) or absence (-) of MLL rearrangements. RESULTS: Homozygosity for a variant IKZF1 allele (rs11978267) increased risk of infantAML [Odds ratio (OR) = 3.9, 95% confidence interval (CI) = 1.8-8.4]; the increased risk was similar for AML/MLL+ and MLL- cases. In contrast, risk of ALL/MLL- was increased in infants homozygous for the IKZF1 variant (OR = 5.1, 95% CI = 1.8-14.5) but the variant did not modify risk of ALL/MLL+. For ARID5B (rs10821936), homozygosity for the variant allele increased risk for the ALL/MLL- subgroup only (OR = 7.2, 95% CI = 2.5-20.6). There was little evidence of an association with the CEBP variant (rs2239633). CONCLUSION:IKZF1 is expressed in early hematopoiesis, including precursor myeloid cells. Our data provide the first evidence that IKZF1 modifies susceptibility to infantAML, irrespective of MLL rearrangements, and could provide important new etiologic insights into this rare and heterogeneous hematopoietic malignancy.
Authors: Kimberly J Johnson; Michelle A Roesler; Amy M Linabery; Joanne M Hilden; Stella M Davies; Julie A Ross Journal: Pediatr Blood Cancer Date: 2010-07-15 Impact factor: 3.167
Authors: Susan E Puumala; Logan G Spector; Melanie M Wall; Leslie L Robison; Nyla A Heerema; Michelle A Roesler; Julie A Ross Journal: Hum Reprod Date: 2010-04-10 Impact factor: 6.918
Authors: M W J C Jansen; L Corral; V H J van der Velden; R Panzer-Grümayer; M Schrappe; A Schrauder; R Marschalek; C Meyer; M L den Boer; W J C Hop; M G Valsecchi; G Basso; A Biondi; R Pieters; J J M van Dongen Journal: Leukemia Date: 2007-02-01 Impact factor: 11.528
Authors: C H Pui; F G Behm; J R Downing; M L Hancock; S A Shurtleff; R C Ribeiro; D R Head; H H Mahmoud; J T Sandlund; W L Furman Journal: J Clin Oncol Date: 1994-05 Impact factor: 44.544
Authors: U Köller; O A Haas; W D Ludwig; C R Bartram; J Harbott; R Panzer-Grümayer; T Hansen-Hagge; J Ritter; U Creutzig; W Knapp Journal: Leukemia Date: 1989-10 Impact factor: 11.528
Authors: Rob Pieters; Martin Schrappe; Paola De Lorenzo; Ian Hann; Giulio De Rossi; Maria Felice; Liisa Hovi; Thierry LeBlanc; Tomasz Szczepanski; Alice Ferster; Gritta Janka; Jeffrey Rubnitz; Lewis Silverman; Jan Stary; Myriam Campbell; Chi-Kong Li; Georg Mann; Ram Suppiah; Andrea Biondi; Ajay Vora; Maria Grazia Valsecchi Journal: Lancet Date: 2007-07-21 Impact factor: 79.321
Authors: Elli Papaemmanuil; Fay J Hosking; Jayaram Vijayakrishnan; Amy Price; Bianca Olver; Eammon Sheridan; Sally E Kinsey; Tracy Lightfoot; Eve Roman; Julie A E Irving; James M Allan; Ian P Tomlinson; Malcolm Taylor; Mel Greaves; Richard S Houlston Journal: Nat Genet Date: 2009-08-16 Impact factor: 38.330
Authors: Alyssa I Clay-Gilmour; Theresa Hahn; Leah M Preus; Kenan Onel; Andrew Skol; Eric Hungate; Qianqian Zhu; Christopher A Haiman; Daniel O Stram; Loreall Pooler; Xin Sheng; Li Yan; Qian Liu; Qiang Hu; Song Liu; Sebastiano Battaglia; Xiaochun Zhu; AnneMarie W Block; Sheila N J Sait; Ezgi Karaesmen; Abbas Rizvi; Daniel J Weisdorf; Christine B Ambrosone; David Tritchler; Eva Ellinghaus; David Ellinghaus; Martin Stanulla; Jacqueline Clavel; Laurent Orsi; Stephen Spellman; Marcelo C Pasquini; Philip L McCarthy; Lara E Sucheston-Campbell Journal: Blood Adv Date: 2017-09-08
Authors: Lindsay A Williams; Jun J Yang; Betsy A Hirsch; Erin L Marcotte; Logan G Spector Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-02-15 Impact factor: 4.254
Authors: Eleni Th Petridou; Marios K Georgakis; Friederike Erdmann; Xiaomei Ma; Julia E Heck; Anssi Auvinen; Beth A Mueller; Logan G Spector; Eve Roman; Catherine Metayer; Corrado Magnani; Maria S Pombo-de-Oliveira; Sameera Ezzat; Michael E Scheurer; Ana Maria Mora; John D Dockerty; Johnni Hansen; Alice Y Kang; Rong Wang; David R Doody; Eleanor Kane; Waffa M Rashed; Nick Dessypris; Joachim Schüz; Claire Infante-Rivard; Alkistis Skalkidou Journal: Eur J Epidemiol Date: 2018-05-14 Impact factor: 8.082
Authors: Kira Young; Matthew A Loberg; Elizabeth Eudy; Logan S Schwartz; Kristina D Mujica; Jennifer J Trowbridge Journal: Exp Hematol Date: 2020-08-06 Impact factor: 3.084